We started funding two new eye treatments that could prevent blindness.
Aflibercept (Eylea) is a newer generation anti-VEGF treatment to preserve and improve vision. It is expected to benefit around 900 people with a range of ophthalmic conditions, including wet age-related macular degeneration and diabetic macular oedema (DMO). DMO is a serious complication of type 1 and 2 diabetes that can cause blindness if untreated.
We also listed dexamethasone implants, providing another treatment option for people with DMO.
Last updated: 25 October 2019